Hologic's (Nasdaq:HOLX) difficult midlife crisis continues. With its core cervical cancer screening business struggling in response to new recommended testing intervals and the 3D tomo mammography business slow to ramp up, Hologic is a distressing mix of sluggish organic growth and a debt-laden balance sheet. While some investors seemed encouraged by the company's move to bring back its former CEO, there's a lot of work to be done to carve out an attractive growth path for this company.
Please read the full article here:
http://www.investopedia.com/stock-analysis/080713/hologic-struggling-find-new-path-holx-dgx-ge-bdx.aspx
Investopedia: Hologic Struggling To Find A New Path
0 comments:
Post a Comment